Julie Hambleton - 10 Feb 2025 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role
Director
Signature
/s/ Francis I. Perier, Jr. as Attorney-in Fact
Issuer symbol
SWTX
Transactions as of
10 Feb 2025
Net transactions value
-$285,720
Form type
4
Filing time
12 Feb 2025, 19:57:25 UTC
Previous filing
29 Jul 2024
Next filing
15 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWTX Common Stock Options Exercise $444,487 +13,774 +336% $32.27 17,869 10 Feb 2025 Direct F1
transaction SWTX Common Stock Sale $730,207 -13,774 -77% $53.01 4,095 10 Feb 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWTX Stock Option (Right to Buy) Options Exercise $0 -13,774 -100% $0.000000 0 10 Feb 2025 Common Stock 13,774 $32.27 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The shares underlying this option are fully vested.